** Shares of vaccine maker Moderna MRNA.O and gene therapy developers fall between 12% and 22% after the U.S. FDA named Vinay Prasad as the director of its Center for Biologics Evaluation and Research (CBER)
** Prasad was a fierce critic of COVID-19 vaccine and mask mandates
** As the director of CBER, Prasad will oversee the regulation of vaccines and gene therapies
** Shares of Moderna down 12.4%, Novavax NVAX.O down 5.2%, while Pfizer PFE.N, previously down after an announcement on medicine costs, extends losses to 3%
** Shares of gene therapy developers such as Sarepta Therapeutics SRPT.O fall 21.5%, Taysha Gene Therapies TSHA.O fall 20.7%, Capricor Therapeutics CAPR.O down 20.3%
** U.S.-listed shares of CRISPR Therapeutics CRSP.BN down 9.6%, Solid Biosciences SLDB.O down 15.3%,
** MRNA down 41.3% and SRPT down 61.1% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。